Factors Predicting the Effi cacy of Adefovir Dipivoxil on Treatment-Naïve Chronic Hepatitis B Patients at 48 Weeks

다국어 초록 (Multilingual Abstract)

Background/Aims: To reveal possible factors predicting the effect of adefovir dipivoxil (ADV) treatment on chronic hepatitis B (CHB) and optimize the utilization of ADV. Methods:In total, 168 treatment-naïve CHB patients were enrolled,including 117 hepatitis B e antigen (HBeAg)-positive patients and 51 HBeAg-negative patients who met the inclusion criteria.
All patients were treated with ADV 10 mg per day for 48 weeks. Multiple logistic regression analyses were used to investigate baseline factors, and responses at weeks 12and 24 were analyzed as predictive values. Results: Multiple regression analyses showed that baseline HBeAg status and HBV DNA levels signifi cantly affected the virological response (VR) (p<0.05), baseline ALT levels were an independent predictor of serological response (SR) (p<0.05) and the body mass index (BMI) may affect the biochemical response (BR)(p<0.05). There was a statistically significant difference in the VR and SR between patients with a primary nonresponse (PNR) at week 12 and those with a VR at week 12 (p<0.01).
Additionally, the VR was significantly different between patients with HBV DNA lower than 10^3 copies/mL at week 24 and those with greater than 10^3 copies/mL (p<0.01).
Conclusions: Patients with negative HBeAg, lower HBV DNA levels and higher ALT values at baseline are more suitable for ADV treatment, whereas patients with lower BMIs may be more amenable to ALT normalization. Adjustments for treatment strategy should be considered if PNR at week 12 or HBV DNA ≥103 copies/mL at week 24 is observed.

참고문헌 (Reference)

1 이헌주, "만성 B형간염 환자에서 adefovir dipivoxil 투여에 의해 발생한 심한 저인산염혈증 1예" 대한간학회 14 (14): 381-386, 2008

2 Xie DY, "The predictive value of ALT, HBeAg and HBV DNA levels at baseline and the degree of HBV suppression at week 12 adefovir dipivoxil treatment to the efficacy of it at week 52 in patients with HBeAg-positive chronic hepatitis B" 16 : 341-344, 2008

3 Husa P, "The effect of patient’s body weight, gender and baseline viral load on the efficacy of hepatitis C therapy" 52 : 590-595, 2006

4 Carrouée-Durantel S, "Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naïve patients is not due to pre-existing drugresistant mutants" 13 : 381-388, 2008

5 Jonas MM, "Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B" 47 : 1863-1871, 2008

6 Keeffe EB, "Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B" 5 : 890-897, 2007

7 Kamar N, "Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients" 71 : 36-42, 2009

8 Ha NB, "Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil" 50 : 727-734, 2009

9 Hass HG, "Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B" 44 : 871-877, 2009

10 Chen EQ, "Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine- resistant hepatitis B virus" 6 : 163-, 2009

11 Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years" 131 : 1743-1751, 2006

12 Marcellin P, "Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B" 48 : 750-758, 2008

13 Lim JK, "Liver transplantation for alcoholic liver disease: current concepts and length of sobriety" 10 (10): S31-S38, 2004

14 Ulcickas Yood M, "Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identified using an automated data algorithm" 15 : 28-36, 2008

15 Poynard T, "Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus" 16 : 203-213, 2009

16 Liaw YF, "Hepatitis B virus infection" 373 : 582-592, 2009

17 Zeng AZ, "Hepatitis B virus genotype-associated variability in antiviral response to adefovir dipivoxil therapy in Chinese Han population" 216 : 205-211, 2008

18 Palumbo E, "Hepatitis B genotypes and response to antiviral therapy: a review" 14 : 306-309, 2007

19 Tseng KC, "HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy" 56 : 813-818, 2009

20 Chinese Society of Hepatology, "Guideline on prevention and treatment of chronic hepatitis B in China (2005)" 120 : 2159-2173, 2007

21 Kurashige N, "Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B" 44 : 601-607, 2009

22 Gallego A, "Evaluation of initial virological response to adefovir and development of adefovir- resistant mutations in patients with chronic hepatitis B" 15 : 392-398, 2008

23 Zhao H, "Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: a randomized, double-blind, multicenter clinical study" 21 : 282-284, 2007

24 European Association for the Study of the Liver, "EASL Clinical Practice Guidelines: management of chronic he patitis B" 50 : 227-242, 2009

25 Gulick RM, "Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359" 186 : 626-633, 2002

26 Zhou G, "Decision of cirrhosis using liver’s ultrasonic images" 4 : 3351-3354, 2005

27 Zeng AZ, "Comparison of antiviral responses to adefovir dipivoxil therapy of genotype B and genotype C HBV infected patients" 16 : 412-415, 2008

28 Wang LC, "Combination of lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy" 17 : 178-184, 2010

29 Lim SG, "Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B" 26 : 1419-1428, 2007

30 오효정, "Association of serum alanine aminotransferase and γ-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease" 대한간학회 17 (17): 27-36, 2011

31 Rodriguez-Frias F, "Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response" 13 : 991-999, 2008

32 Baker DE, "Adefovir dipivoxil: focus on its use in the treatment of chronic hepatitis B" 5 : 89-100, 2005

33 Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAgnegative chronic hepatitis B" 45 : 307-313, 2007

34 Keeffe EB, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update" 6 : 1315-1341, 2008